SCYNEXIS (SCYX) Expected to Announce Quarterly Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

SCYNEXIS (NASDAQ:SCYX) last announced its earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.13. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%. The business had revenue of $0.98 million during the quarter.

SCYNEXIS Price Performance

Shares of NASDAQ SCYX opened at $0.95 on Monday. The company has a market cap of $36.92 million, a PE ratio of -1.28 and a beta of 1.65. SCYNEXIS has a 1-year low of $0.73 and a 1-year high of $3.07. The stock has a fifty day moving average price of $0.95 and a 200 day moving average price of $1.10.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on SCYNEXIS in a report on Thursday, May 1st. They issued a “hold” rating for the company.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.